Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Sinonasal undifferentiated carcinoma 1Neoplasms 1Myeloproliferative Disorders 1Lymphoma, T-Cell 1Leukemia, Biphenotypic, Acute 1Esthesioneuroblastoma, Olfactory 1Chondrosarcoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 8fludarabine phosphate 7fludarabine 5Busulfan 5Mycophenolic Acid 4Melphalan 4Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Filgrastim 3Azacitidine 3venetoclax 2thymoglobulin 2Tacrolimus 2Rituximab 2Injections 2Hematopoietic Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2Cytarabine 2Cyclosporins 2Clofarabine 2Bone Marrow Transplantation 2Antilymphocyte Serum 2sulforaphane 1ruxolitinib 1pegylated granulocyte colony-stimulating factor 1monalizumab 1ivosidenib 1enasidenib 1cedazuridine 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Anemia, Refractory, with Excess of Blasts × enasidenib × Clear all
NCT03383575 2026-02-17

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
63 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡